

Resource Summary Report

Generated by [RRID](#) on Aug 28, 2026

HCC1419

RRID:CVCL_1251

Type: Cell Line

Proper Citation

RRID:CVCL_1251

Cell Line Information

URL: https://web.expasy.org/cellosaurus/CVCL_1251

Proper Citation: RRID:CVCL_1251

Description: Cell line HCC1419 is a Cancer cell line with a species of origin Homo sapiens (Human)

Sex: Female

Disease: Breast ductal carcinoma

Defining Citation: [PMID:9833771](#), [PMID:9865903](#), [PMID:11314036](#), [PMID:19582160](#), [PMID:22460905](#), [PMID:22585861](#), [PMID:23601657](#), [PMID:24176112](#), [PMID:25485619](#), [PMID:25877200](#), [PMID:25960936](#), [PMID:26589293](#), [PMID:27397505](#), [PMID:28196595](#), [PMID:30894373](#), [PMID:31068700](#), [PMID:35839778](#)

Comments: Miscellaneous: Direct author submission of STR profile from Girard, Luc & Gazdar, Adi F., Part of: MD Anderson Cell Lines Project., Part of: JWGray breast cancer cell line panel., Part of: ICBP43 breast cancer cell line panel., Part of: COSMIC cell lines project., Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).

Category: Cancer cell line

Organism: Homo sapiens (Human)

Name: HCC1419

Synonyms: HCC-1419, Hamon Cancer Center 1419

Cross References: CLO:CLO_0003636, EFO:EFO_0005372, ArrayExpress:E-MTAB-783, ArrayExpress:E-MTAB-2706, ArrayExpress:E-MTAB-2770, ArrayExpress:E-MTAB-3610, ATCC:CRL-2326, BioGRID_ORCS_Cell_line:665, BioSample:SAMN03471438, BioSample:SAMN10988522, cancercellines:CVCL_1251,

Cell_Model_Passport:SIDM00882, ChEMBL-Cells:CHEMBL3308738, ChEMBL-Targets:CHEMBL1075455, Cosmic:687475, Cosmic:904363, Cosmic:907045, Cosmic:1287884, Cosmic:1308992, Cosmic:1603201, Cosmic:1935005, Cosmic:2165005, Cosmic-CLP:907045, DepMap:ACH-000277, EGA:EGAS00001000610, EGA:EGAS00001000978, EGA:EGAS00001002554, GDSC:907045, GEO:GSM149984, GEO:GSM149992, GEO:GSM150000, GEO:GSM186716, GEO:GSM186717, GEO:GSM217573, GEO:GSM219874, GEO:GSM274661, GEO:GSM344371, GEO:GSM344421, GEO:GSM350553, GEO:GSM378145, GEO:GSM459729, GEO:GSM783940, GEO:GSM844544, GEO:GSM847322, GEO:GSM887038, GEO:GSM888108, GEO:GSM984231, GEO:GSM1053722, GEO:GSM1172864, GEO:GSM1374498, GEO:GSM1421430, GEO:GSM1669844, IARC_TP53:21361, IARC_TP53:22811, IARC_TP53:30202, KCLB:9S1419, LiGeA:CCLE_174, LINCS_HMS:50207, LINCS_LDP:LCL-1314, PharmacDB:HCC1419_474_2019, PRIDE:PXD030304, Progenetix:CVCL_1251, PubChem_Cell_line:CVCL_1251, SLKBase:3514, Wikidata:Q54881567

ID: CVCL_1251

Record Creation Time: 20220427T220317+0000

Record Last Update: 20260815T233702+0000

Ratings and Alerts

No rating or validation information has been found for HCC1419.

No alerts have been found for HCC1419.

Data and Source Information

Source: [Cellosaurus](#)

Usage and Citation Metrics

We found 128 mentions in open access literature.

Listed below are recent publications. The full list is available at [RRID](#) .

Siegel F, et al. (2026) Sevabertinib, a Reversible HER2 Inhibitor with Activity in Lung Cancer. Cancer discovery, 16(1), 81.

Pequerul R, et al. (2025) Inter- and intra-tumoral ALDH1 heterogeneity in breast cancer identifies therapeutic opportunities for ALDH1A-specific inhibitors. Cell chemical biology.

Vykoukal J, et al. (2025) Vesicle-mediated mitochondrial clearance presents an actionable metabolic vulnerability in triple-negative breast cancer. Cell reports. Medicine, 6(12), 102478.

Duan L, et al. (2025) Coinhibition of Aurora Kinase B and SUV4-20H Induces Synthetic Lethality in Wild-type p53-Deficient Cancer Cells. Molecular cancer therapeutics, 24(7),

Ishibashi K, et al. (2024) Astrocyte-induced mGluR1 activates human lung cancer brain metastasis via glutamate-dependent stabilization of EGFR. *Developmental cell*, 59(5), 579.

Moyer CL, et al. (2024) IRX4204 Induces Senescence and Cell Death in HER2-positive Breast Cancer and Synergizes with Anti-HER2 Therapy. *Clinical cancer research : an official journal of the American Association for Cancer Research*, 30(11), 2558.

Hlavaty SI, et al. (2024) ACSS1-dependent acetate utilization rewires mitochondrial metabolism to support AML and melanoma tumor growth and metastasis. *Cell reports*, 43(12), 114988.

Moon SJ, et al. (2023) CTTN Overexpression Confers Cancer Stem Cell-like Properties and Trastuzumab Resistance via DKK-1/WNT Signaling in HER2 Positive Breast Cancer. *Cancers*, 15(4).

Wei L, et al. (2023) Pharmacological Targeting of Androgen Receptor Elicits Context-Specific Effects in Estrogen Receptor-Positive Breast Cancer. *Cancer research*, 83(3), 456.

Liu S, et al. (2023) Targeting CXCR4 abrogates resistance to trastuzumab by blocking cell cycle progression and synergizes with docetaxel in breast cancer treatment. *Breast cancer research : BCR*, 25(1), 62.

Kim TW, et al. (2023) Nodakenin Induces ROS-Dependent Apoptotic Cell Death and ER Stress in Radioresistant Breast Cancer. *Antioxidants (Basel, Switzerland)*, 12(2).

Weisser NE, et al. (2023) An anti-HER2 biparatopic antibody that induces unique HER2 clustering and complement-dependent cytotoxicity. *Nature communications*, 14(1), 1394.

Costantini S, et al. (2022) An Integrated In Silico, In Vitro and Tumor Tissues Study Identified Selenoprotein S (SELENOS) and Valosin-Containing Protein (VCP/p97) as Novel Potential Associated Prognostic Biomarkers in Triple Negative Breast Cancer. *Cancers*, 14(3).

Rivas EI, et al. (2022) Targeted immunotherapy against distinct cancer-associated fibroblasts overcomes treatment resistance in refractory HER2+ breast tumors. *Nature communications*, 13(1), 5310.

Liu M, et al. (2022) INHBA is a mediator of aggressive tumor behavior in HER2+???basal breast cancer. *Breast cancer research : BCR*, 24(1), 18.

Gutierrez DA, et al. (2022) Identification of a Potent Cytotoxic Pyrazole with Anti-Breast Cancer Activity That Alters Multiple Pathways. *Cells*, 11(2).

Schuster C, et al. (2022) Combinatorial Effects of the Natural Products Arctigenin, Chlorogenic Acid, and Cinnamaldehyde Commit Oxidation Assassination on Breast Cancer Cells. *Antioxidants (Basel, Switzerland)*, 11(3).

Flint AL, et al. (2022) Modified Curcumins as Potential Drug Candidates for Breast Cancer: An Overview. *Molecules* (Basel, Switzerland), 27(24).

Wang B, et al. (2022) A miR-34a-guided, tRNAⁱMet-derived, piR_019752-like fragment (tRiMetF31) suppresses migration and angiogenesis of breast cancer cells via targeting PFKFB3. *Cell death discovery*, 8(1), 355.

Gu Y, et al. (2022) TRAF4 hyperactivates HER2 signaling and contributes to Trastuzumab resistance in HER2-positive breast cancer. *Oncogene*, 41(35), 4119.